Company: PCRX
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001396814-25-000061
Chunk: 39

Company: Pacira BioSciences, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 39
---
,544)$1,351 $798,541  

Common StockAdditionalPaid-InCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncomeSharesAmountTotalBalance at December 31, 202346,481 $46 $976,633 $(106,796)$247 $870,130 Vested restricted stock units36 1 — — — 1 Common stock withheld for employee withholding tax liabilities on vested restricted stock units— — (4)— — (4)Stock-based compensation— — 13,151 — — 13,151 Other comprehensive loss (Note 11)— — — — (95)(95)Net income— — — 8,979 — 8,979 Balance at March 31, 202446,517 $47 $989,780 $(97,817)$152 $892,162 

See accompanying notes to condensed consolidated financial statements.

Pacira BioSciences, Inc.  |  Q1 2025 Form 10-Q  |  Page 7

PACIRA BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 (In thousands)

(Unaudited)

Three Months EndedMarch 31, 20252024Operating activities:  Net income$4,812 $8,979 Adjustments to reconcile net income to net cash provided by operating activities:  Deferred taxes1,397 3,463 Depreciation of fixed assets and amortization of intangible assets21,168 18,426 Amortization of debt issuance costs845 681 Amortization of debt discount22 24 Stock-based compensation14,553 13,151 Changes in contingent consideration(2,675)(3,806)Other net (gains) losses(5,887)73 Changes in operating assets and liabilities:  Accounts receivable, net8,559 3,917 Inventories, net(8,472)7,572 Prepaid expenses and other assets(7,111)897 Accounts payable2,464 (6,976)Accrued expenses and income taxes payable4,702 3,471 Other liabilities1,082 (771)Net cash provided by operating activities35,459 49,101 Investing activities:  Acquisition of